GENFIT Stock Euronext Paris
Equities
GNFT
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- PTS | - |
Sales 2024 * | 89.63M 96.53M 0 132M | Sales 2025 * | 48.78M 52.54M 0 71.83M | Capitalization | 172M 186M 0 254M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.15M - 22.09M | Net income 2025 * | -21M -22.62M - -30.92M | EV / Sales 2024 * | 1.61 x |
Net cash position 2024 * | 27.6M 29.72M 0 40.64M | Net cash position 2025 * | 44.9M 48.35M 0 66.11M | EV / Sales 2025 * | 2.61 x |
P/E ratio 2024 * |
7.37
x | P/E ratio 2025 * |
26.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.71% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- GNFT Stock
- GNFT Stock